Sofinnova Investments’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Sofinnova Investments’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-60,000	Closed	-$5.84M	–	84
2020 Q3	$5.84M	Buy	+60,000	New	+$7.5M	0.43%	43
2019 Q4	–	Sell	-148,600	Closed	-$11.9M	–	76
2019 Q3	$11.9M	Buy	+148,600	New	+$12.6M	1.08%	25

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sofinnova Investments's RETA Position: Q3 2023 in Review

Sofinnova Investments sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 322,471 shares — an estimated $32.9M sold.

Sofinnova Investments first reported a position in RETA in Q1 2018 and held it in 18 quarters. The position peaked at $57.1M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Sofinnova Investments reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Sofinnova Investments sold 322,471 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $32.9M.
Sofinnova Investments first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 18 quarters.
Sofinnova Investments's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $57.1M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Sofinnova Investments's 13F filing for Q3 2023, filed 14 Nov 2023.